Statement of Changes in Beneficial Ownership (Form 4)

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person * Pittman Scott M. 2. Issuer Name and Ticker or Trading Symbol Nuo Therapeutics, Inc. [AURX] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director __X__ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) C/O NUO THERAPEUTICS, INC., 8285 EL RIO, SUITE190 3. Date of Earliest Transaction (Month/Day/Year) 05/29/2026 (Street) HOUSTON, TX 77054 4. If Amendment, Date Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.		SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)

2. Conversion or Exercise Price of Derivative Security

3. Transaction Date (Month/Day/Year)

3A. Deemed Execution Date, if any (Month/Day/Year)

4. Transaction Code (Instr. 8)

5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)

6. Date Exercisable and Expiration Date (Month/Day/Year)

7. Title and Amount of Underlying Securities (Instr. 3 and 4)

8. Price of Derivative Security (Instr. 5)

9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)

10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)

11. Nature of Indirect Beneficial Ownership (Instr. 4)

Code

V

(A)

(D)

Date Exercisable

Expiration Date

Title

Amount or Number of Shares

Interim Warrant (right to buy)(1)

$1.5

05/29/2026(2)

A

17,450

05/29/2026

01/23/2031

Common Stock

17,450

$1.5

17,450

D

Second Warrant (right to buy)(3)

$1.5

05/29/2026(2)

D(4)

36,750

09/30/2026

01/23/2031

Common Stock

36,750

$1.5

0

D

Prepayment Warrant (right to buy)

$1.5

05/29/2026(2)

D(5)

7,516

01/23/2026

01/23/2031

Common Stock

7,516

$1.5

0

D

Second Restated Warrant (right to buy)

$1.5

05/29/2026(2)

A(4)

17,500

09/30/2026(6)

01/23/2031

Common Stock

17,500

$1.5

0

D

Prepayment Restated Warrant (right to buy)

$1.5

05/29/2026(2)

A(5)

7,333(7)

05/29/2026(8)

01/23/2031

Common Stock

7,333

$1.5

0

D

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Pittman Scott M. C/O NUO THERAPEUTICS, INC. 8285 EL RIO, SUITE190 HOUSTON, TX 77054	X	X

Signatures

/s/ David Jorden, attorney-in-fact		06/02/2026
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	Represents Origination Interim and Capital Interim Warrants.
(2)	Transaction approved by Board of Directors of Issuer and Non-Employee Directors
(3)	Represents Origination Restated Second and Capital Restated Second Warrants.
(4)	Previously issued Second Warrants cancelled for Second Restated Warrants with same terms, including same exercise price (and cancelled on date when underlying Common Stock traded at lower price than when previously issued), in accordance with the Amended and Restated Loan and Security Agreement dated May 29, 2026 among the Issuer, the Reporting Person, and other parties thereto (the "Loan Agreement").
(5)	Previously issued Prepayment Warrants cancelled for Prepayment Restated Warrants with same terms, including same exercise price (and cancelled on date when underlying Common Stock traded at lower price than when previously issued), in accordance with the Loan Agreement.
(6)	Vesting (if at all) on September 30, 2026 provided a Second Funding occurs in accordance with the Loan Agreement.
(7)	Represents maximum number of shares issuable (if at all) in the event of a Prepayment in accordance with the Loan Agreement.
(8)	Vesting (if at all) upon the occurrence of a Prepayment, but no later than December 31, 2028, in accordance with the Loan Agreement.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.